TY - JOUR T1 - Dual-tracer PET/CT protocol with [<sup>18</sup>F]-FDG and [<sup>68</sup>Ga]Ga-FAPI-46 for cancer imaging - a proof of concept. JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.122.263835 SP - jnumed.122.263835 AU - Katrin S Roth AU - Conrad-Amadeus Voltin AU - Lutz van-Heek AU - Simone Wegen AU - Klaus Schomaecker AU - Thomas Fischer AU - Simone Marnitz AU - Alexander E. Drzezga AU - Carsten Kobe Y1 - 2022/04/01 UR - http://jnm.snmjournals.org/content/early/2022/04/14/jnumed.122.263835.abstract N2 - Imaging studies with PET tracers acting as fibroblast activation protein inhibitors (FAPI) show promising results that could usefully complement [18F]-FDG in cancer imaging. Methods: All patients received [18F]-FDG-PET/CT and dual-tracer PET/CT after additional injection of [68Ga]Ga-FAPI-46 following the [18F]-FDG-PET/CT. Two readers visually compared detection rate and analyzed target-to-background uptake ratios (TBRs) for tumor and metastatic tissue in single and dual-tracer PET/CT. Results: Detection rate in dual-tracer PET/CT was visually as good as that in single-tracer PET/CT in four patients and superior in two patients, whereas TBRs were significantly higher in dual-tracer PET/CTs. Conclusion: We demonstrate the feasibility and potential of dual-tracer [18F]-FDG-[68Ga]Ga-FAPI-46-PET/CT administered within a single session. The dual-tracer approach may have superior sensitivity to [18F]-FDG-PET/CT alone without compromising individual assessment of either scan. ER -